Table 1

Baseline characteristics of the cohort

Characteristicn=80
Age, years
 Median (range)65 (34–85)
Origin of cancer (WHO 2003 classification), n (%)
 Ovary/fallopian tube63 (79)
 Primary peritoneal17 (21)
Histology, n (%)
 High-grade serous80 (100)
FIGO stage, n (%)
 IIIC53 (66)
 IV27 (34)
Outcome of debulking surgery, n (%)
 No residual disease59 (74)
 >0 but ≤1 cm residual disease11 (14)
 >1 cm residual disease10 (12)
Cycles of neoadjuvant chemotherapy, n (%)
 3 or 4 cycles74 (93%)
 >4 cycles6 (7%)
Regimen of neoadjuvant chemotherapy, n (%)
 Carboplatin + paclitaxel70 (88)
 Carboplatin9 (11)
 Other1 (1)
In total ≥6 cycles chemotherapy (neoadjuvant + adjuvant), n (%)73* (91)
Intraperitoneal chemotherapy, n (%)4 (5)
  • *In 14 patients, bevacizumab was part of the chemotherapeutic regimen.

  • FIGO, International Federation of Gynecology and Obstetrics.